Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 positive |
| Therapy | NU6027 + Temozolomide |
| Indication/Tumor Type | ovarian cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 positive | ovarian cancer | predicted - sensitive | NU6027 + Temozolomide | Preclinical - Cell culture | Actionable | In a preclinical study, NU6027 enhanced the efficacy of Temodar (temozolomide) in ovarian cancer cells with mismatch repair activity and positive for TP53 in culture, demonstrating a 50% greater decrease in cell survival compared to Temodar (temozolomide) alone (PMID: 21730979). | 21730979 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21730979) | Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. | Full reference... |